5 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On

3. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 83

 Bristol-Myers Squibb Company (NYSE:BMY) is among the Best Pharmaceutical Stocks.

On June 2, Bristol-Myers Squibb Company (NYSE:BMY) and SystImmune announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported interim Phase 3 data. It showed that izalontamab brengitecan had statistically significant progress in overall survival and progression-free survival in advanced triple-negative breast cancer and esophageal squamous cell carcinoma. Presenting the results at the 2026 American Society of Clinical Oncology meeting, in TNBC, Iza-bren delivered a median overall survival of 15.9 months as compared to 12.5 months and progression-free survival of 8.5 months versus 3.1 months. It improved the confirmed objective response rate to 51.7% versus 20.5% compared with the physician’s choice of chemotherapy.

In esophageal cancer, SystImmune said iza-bren posted a median overall survival of 9.8 months compared to 7.2 months and progression-free survival of 4.2 months versus 2.0 months. It raised the objective response rate to 35.3% from 13.1%. The companies said safety remained manageable, with predominantly hematologic adverse events and low interstitial lung disease rates.

Bristol-Myers Squibb Company (NYSE:BMY) is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.